Abstract: In a distributed processing management apparatus, server 3 has a node table 5, a job management table 6 and a job class table 7 in order to manage the resource status such as the CPU operating ratio of each node in every predetermined time period. When the operating ratio of the CPU and other elements of a node rises after the input of a job and the speed of executing the input job falls, the server 3 re-inputs the job from the current node 2a to some other node 2b. With this arrangement, it is possible to improve the overall TAT and effectively exploit computer resources in grid computer environment.

Abstract: An inactivating device for inactivating virus, bacteria, etc. including a humidifying unit for humidifying flowing air, a humidifying water supply unit for supplying the humidifying unit with humidifying water containing active oxygen species achieved by electrolyzing tap water, and a concentration adjusting unit for adjusting the concentration of the active oxygen species in the humidifying water to a predetermined concentration.

Abstract: A method for verifying a logical equivalency between two logic circuits having different combinational logic circuits includes the steps of converting into a logic circuit a logic cone that has been determined for each of the two logic circuits, the logic cone including all inputs and all logic circuits which affect one output of the combinational logic circuit, storing a logical expression converted by the converting step and a logic circuit element included in the logic cone while correlating the logical expression with the logic circuit element, and specifying the logic circuit element corresponding to a specified term in the logical expression that has been converted.

Abstract: Preparations to be administered for treating or preventing ischemic diseases or arterial diseases which contain Hepatocyte growth factor (HGF) as an active ingredient. The preparations provide such effect that HGF concentration in an affected region to which HGF was administered is maintained, a half-life is longer, a dose can be reduced, and other organs except the affected region are less affected in comparison with intravenous administration.

Abstract: The invention relates to a method for decomposing bromate ions contained in a liquid. The method includes the sequential steps of bringing the liquid into contact with a photocatalyst; and irradiating the photocatalyst with a light ray having an energy that is not lower than that of a band gap of the photocatalyst, thereby generating a photocatalytic reaction to decompose the bromate ions. The invention further relates an apparatus for decomposing bromate ions contained in a liquid. The apparatus includes a first section for generating therein a photocatalytic reaction to decompose the bromate ions; a photocatalyst adapted to be brought into contact with the liquid in the first section; and a light source for irradiating the photocatalyst with the light ray such that the photocatalytic reaction is generated in the first section when the photocatalyst is in contact with the liquid. Thus, it is possible to efficiently and stably decompose the bromate ions.

Abstract: Modified BDNF having improved pharmacological activities, pharmacokinetics and physical properties can be obtained by modifying BDNF with a 1-acyl-glycerol derivative. This BDNF being modified with a 1-acyl-glycerol derivative of the present invention has more efficacious and more excellent pharmacokinetic properties with retaining the useful effects being characteristic to BDNF which are useful as remedies for neurodegenerative diseases and diabetes mellitus, and hence, it is particularly useful as a therapeutic agent for treatment of type 2 diabetes mellitus.

Abstract: Working machinery for working an elongated work comprises a work stocker configured to store a plurality of works, a work carrying-in machine configured to carry in the works from the work stocker to a working area, a positioning device configured to position the work in the working area, a work clamper provided in the working area and configured to clamp the work in a vertical direction, a plurality of working machines arranged on both sides of the working clamper to work the elongated work from both sides of the work, a plurality of driving devices configured to move the working machines respectively in a longitudinal direction, a controller configured to control the working machines and the driving device, and a work carrying-out machine configured to carry out the work which is completed in working from the working area.

Abstract: A method for verifying a logical equivalency between two logic circuits having different combinational logic circuits includes the steps of converting into a logic circuit a logic cone that has been determined for each of the two logic circuits, the logic cone including all inputs and all logic circuits which affect one output of the combinational logic circuit, storing a logical expression converted by the converting step and a logic circuit element included in the logic cone while correlating the logical expression with the logic circuit element, and specifying the logic circuit element corresponding to a specified term in the logical expression that has been converted.

Abstract: Working machinery for working an elongated work comprises a work stocker configured to store a plurality of works, a work carrying-in machine configured to carry in the works from the work stocker to a working area, a positioning device configured to position the work in the working area, a work clamper provided in the working area and configured to clamp the work in a vertical direction, a plurality of working machines arranged on both sides of the working clamper to work the elongated work from both sides of the work, a plurality of driving devices configured to move the working machines respectively in a longitudinal direction, a controller configured to control the working machines and the driving device, and a work carrying-out machine configured to carry out the work which is completed in working from the working area.

Abstract: Modified BDNF having improved pharmacological activities, pharmacokinetics and physical properties can be obtained by modifying BDNF with a 1-acyl-glycerol derivative. This BDNF being modified with a 1-acyl-glycerol derivative of the present invention has more efficacious and more excellent pharmacokinetic properties with retaining the useful effects being characteristic to BDNF which are useful as remedies for neurodegenerative diseases and diabetes mellitus, and hence, it is particularly useful as a therapeutic agent for treatment of type 2 diabetes mellitus.

Abstract: An apparatus is provided for automatically modifying serious semantic grammar errors in an HDL description and to clearly show the modified portions. For these purposes, the apparatus includes: means for detecting a portion in which variables on the right and the left sides of an assignment statement are inconsistent in type; a template for converting the type of the variable on the right side of the assignment statement into that of the variable on the left side; means for modifying the portion into a correct description by applying the type conversion function to the right side of the assignment statement having the portion; and means for attaching a comment about the modification to the modified portion, and is used to automatically modify inappropriate descriptions in the design information of an electronic system or of a logic circuit described in a hardware description language such as VHDL and Verilog-HDL.

Abstract: The present invention provides a therapeutic agent for treatment of diabetes and hyperlipemia, especially a therapeutic agent for treatment of type II diabetes mellitus, which comprises as the active ingredient a neurotrophic factor such as BDNF (brain-derived neurotrophic factor), ligands of trkB or trkC receptors, NGF, NT-3, NT-4/5, CNTF, GDNF, HGF, etc. Different from conventional oral hypoglycemic agents being mainly used in the treatment of type II diabetes mellitus, the agent of the present invention exhibit blood lipid regulating effects and body fat accumulation regulating effects, in addition to the blood glucose regulating effects. Thus, the agent of the present invention are novel, and can reduce the risk factors in diabetes accompanied by hyperlipemia or obesity, without using any other agent.

Abstract: In a method of amplifying optical input signals over a wide bandwidth, the optical input signals are applied to an optical waveguide made from a rare-earth-doped amorphous yttrium aluminum oxide material (e.g., erbium-doped yttrium aluminum oxide material). The optical input signals include optical signals having wavelengths shorter than 1,520 nanometers and optical signals having wavelengths longer than 1,610 nanometers. Preferably, the wavelengths range from as short as approximately 1,480 nanometers to as long as approximately 1,650 nanometers. Pump light is applied to the optical waveguide to cause the waveguide to provide optical gain to the optical input signals.

Abstract: The present invention provides a therapeutic agent for treatment of diabetes and hyperlipemia, especially a therapeutic agent for treatment of type II diabetes mellitus, which comprises as the active ingredient a neurotrophic factor such as BDNF (brain-derived neurotrophic factor), ligands of trkB or trkC receptors, NGF, NT-3, NT-4/5, CNTF, GDNF, HGF, etc. Different from conventional oral hypoglycemic agents being mainly used in the treatment of type II diabetes mellitus, the agent of the present invention exhibit blood lipid regulating effects and body fat accumulation regulating effects, in addition to the blood glucose regulating effects. Thus, the agent of the present invention are novel, and can reduce the risk factors in diabetes accompanied by hyperlipemia or obesity, without using any other agent.

Abstract: The invention relates to a method for decomposing bromate ions contained in a liquid. The method includes the sequential steps of bringing the liquid into contact with a photocatalyst; and irradiating the photocatalyst with a light ray having an energy that is not lower than that of a band gap of the photocatalyst, thereby generating a photocatalytic reaction to decompose the bromate ions. The invention further relates an apparatus for decomposing bromate ions contained in a liquid. The apparatus includes a first section for generating therein a photocatalytic reaction to decompose the bromate ions; a photocatalyst adapted to be brought into contact with the liquid in the first section; and a light source for irradiating the photocatalyst with the light ray such that the photocatalytic reaction is generated in the first section when the photocatalyst is in contact with the liquid. Thus, it is possible to efficiently and stably decompose the bromate ions.

Abstract: L-ascorbic acid, L-ascorbic acid derivatives and salts thereof can reduce lactic acid levels in blood, and are useful for treating lactic acidosis and the like caused by administration of amoxapine, theophylline, metformin, phenformin, buformin, nalidixic acid, hopantenic acid, azidothymidine, dideoxycytidine, high caloric transfusion, propylene glycol, ethylene glycol, xylitol, lactose, sorbitol or the like.

Abstract: The present invention provides a therapeutic agent for treatment of diabetes and hyperlipemia, especially a therapeutic agent for treatment of type II diabetes mellitus, which comprises as the active ingredient a neurotrophic factor such as BDNF (brain-derived neurotrophic factor), ligands of trkB or trkC receptors, NGF, NT-3, NT-4/5, CNTF, GDNF, HGF, etc. Different from conventional oral hypoglycemic agents being mainly used in the treatment of type II diabetes mellitus, the agent of the present invention exhibit blood lipid regulating effects and body fat accumulation regulating effects, in addition to the blood glucose regulating effects. Thus, the agent of the present invention are novel, and can reduce the risk factors in diabetes accompanied by hyperlipemia or obesity, without using any other agent.

Abstract: The invention relates to a method for decomposing bromate ions contained in a liquid. The method includes the sequential steps of bringing the liquid into contact with a photocatalyst; and irradiating the photocatalyst with a light ray having an energy that is not lower than that of a band gap of the photocatalyst, thereby generating a photocatalytic reaction to decompose the bromate ions. The invention further relates to an apparatus for decomposing bromate ions contained in a liquid. The apparatus includes a first section for generating therein a photocatalytic reaction to decompose the bromate ions; a photocatalyst adapted to be brought into contact with the liquid in the first section; and a light source for irradiating the photoacatalyst with the light ray such that the photocatalytic reaction is generated in the first section when the photocatalyst is in contact with the liquid.

Abstract: Human ciliary neurotrophic factor (human CNTF) mutants, in which at least the amino acid residue corresponding to position 153 of wild type human CNTF has been substituted with another amino acid residue in the amino acid sequence encoding human CNTF, exhibit an activity comparable or superior to that of wild type human CNTF. It is therefore expected that the human CNTF mutants would be effective as drugs with improved side effects such as reduction in appearance of an autoantibody, loss of body weight, anorexia, a dry cough, fatigue, etc.In cytokines having sequence similarity to human CNTF and abundant .alpha. helices (GH, PRL, EPO, G- CSF, LIF, IL-6, IL-2, IL-4, GM-CSF), there are further provided mutants in the D1 cap region.

Abstract: A refrigerant distribution unit 10 is an integrated structure comprising: a multiplicity of branch tubes 12a-12c connectable with a multiplicity of indoor units 1a-1c; a distributor 11, connected with one refrigerant tube 5a extending from an outdoor unit for receiving refrigerant from the outdoor unit, the distributor distributing the refrigerant to the multiple branch tubes 12a-12c; and electric valves 15 provided one in each of the branch tubes 12a-12c for controlling the flows of refrigerant that pass through the respective branch tubes; and a case for enclosing the flow control unit. The refrigerant distribution unit 10 enables distribution of optimal amounts of refrigerant to all of the coexisting indoor units 1a-1e, even when the indoor units 1d-1e have much larger heat capacities than the indoor units 1a-1c.